Elliot B Tapper1, Vilas R Patwardhan, Michael Curry. 1. Division of Gastroenterology, Beth Israel Deaconess Medical Center, Deaconess 309, 330 Brookline Avenue, Boston, MA, 02215, USA, etapper@bidmc.harvard.edu.
Abstract
BACKGROUND: Alpha-1 antitrypsin (AAT) deficiency is often evaluated in patients with liver disease of unknown etiology. AIMS: We aimed to describe the practice and yield of AAT testing at a large clinical laboratory. METHODS: This is the retrospective cohort study of all patients with AAT measurements at one major clinical laboratory between 2003 and 2012. RESULTS: AAT was measured in 4,985 patients by more than 339 physicians. Eight (0.16 %) patients were found to have AAT deficiency disease. Low AAT levels were associated with two clinical factors. Aspartate aminotransferase (>40 IU/L) was inversely related, odds ratio (OR) 0.53, 95 % CI (0.32-0.88), while comorbid pulmonary disease was positively correlated, OR 4.00, 95 % CI (1.37-9.30). Non-directed testing was common. More than 90 % of patients with ALT > 40 were simultaneously assessed for AAT deficiency, hepatitis B or C, hemochromatosis, and autoimmune hepatitis. Rates of phenotype utilization were low for patients with low AAT (23, 31.5 %). Phenotype utilization was inversely related to the practice of simultaneous testing for simultaneous autoimmune hepatitis [OR 0.34 (95 % CI 0.13-0.88)], hepatitis B [OR 0.32 (95 % CI 0.11-0.89)], hepatitis C [OR 0.36 (95 % CI 0.13-1.00)], and Wilson disease evaluation [OR 0.35 (95 % CI 0.14-0.92)]. CONCLUSION: The yield of AAT testing for patients with elevated liver enzymes is low. Utilization of phenotype testing is low and related to non-directed liver testing patterns. These data suggest a role for guidelines and laboratory protocols to encourage directed testing and phenotype utilization.
BACKGROUND:Alpha-1 antitrypsin (AAT) deficiency is often evaluated in patients with liver disease of unknown etiology. AIMS: We aimed to describe the practice and yield of AAT testing at a large clinical laboratory. METHODS: This is the retrospective cohort study of all patients with AAT measurements at one major clinical laboratory between 2003 and 2012. RESULTS:AAT was measured in 4,985 patients by more than 339 physicians. Eight (0.16 %) patients were found to have AAT deficiency disease. Low AAT levels were associated with two clinical factors. Aspartate aminotransferase (>40 IU/L) was inversely related, odds ratio (OR) 0.53, 95 % CI (0.32-0.88), while comorbid pulmonary disease was positively correlated, OR 4.00, 95 % CI (1.37-9.30). Non-directed testing was common. More than 90 % of patients with ALT > 40 were simultaneously assessed for AAT deficiency, hepatitis B or C, hemochromatosis, and autoimmune hepatitis. Rates of phenotype utilization were low for patients with low AAT (23, 31.5 %). Phenotype utilization was inversely related to the practice of simultaneous testing for simultaneous autoimmune hepatitis [OR 0.34 (95 % CI 0.13-0.88)], hepatitis B [OR 0.32 (95 % CI 0.11-0.89)], hepatitis C [OR 0.36 (95 % CI 0.13-1.00)], and Wilson disease evaluation [OR 0.35 (95 % CI 0.14-0.92)]. CONCLUSION: The yield of AAT testing for patients with elevated liver enzymes is low. Utilization of phenotype testing is low and related to non-directed liver testing patterns. These data suggest a role for guidelines and laboratory protocols to encourage directed testing and phenotype utilization.
Authors: David R Nelson; Jeffrey Teckman; Adrian M Di Bisceglie; David A Brenner Journal: Clin Gastroenterol Hepatol Date: 2011-12-23 Impact factor: 11.382
Authors: Melissa R Snyder; Jerry A Katzmann; Malinda L Butz; Carmen Wiley; Ping Yang; D Brian Dawson; Kevin C Halling; W Edward Highsmith; Stephen N Thibodeau Journal: Clin Chem Date: 2006-10-19 Impact factor: 8.327